_256_384.png)
The company plans a phased expansion across India, focusing initially on metro cities and early-adoption hubs
The lens received U.S. Food and Drug Administration (FDA) market authorization via the De Novo pathway in late 2025
The first Phase III and second Phase III trials will be multi-centre, randomised, assessor-blind, active-comparator studies to determine the efficacy, safety and tolerability of orally administered Zintrodiazine
The study evaluated oral semaglutide in young patients with type 2 diabetes and found it delivered a superior reduction in HbA1c
The company announced that its Phase III FENhance 1 and 2 studies both met their primary endpoints
Pharma giant targets new standards of care
The study is being conducted through its Japan-based pharmaceutical arm, Asahi Kasei Therapeutics Corp
If approved, the move would significantly broaden the use of KEYTRUDA and KEYTRUDA QLEX in combination with Padcev
Together, the companies aim to deliver an integrated toolkit for biomarker discovery and clinical research
SBE303 targets Nectin-4, an adhesion protein overexpressed in multiple tumor types, including urothelial, lung, and breast cancers
Subscribe To Our Newsletter & Stay Updated
